Comparing Safety and Effectiveness of Merils Myval Transcatheter Heart Valve Series Versus Edwardss Sapien and Medtronics Evolut Valves in Severe Symptomatic Native Aortic Valve Stenosis
Led by Meril Life Sciences Pvt. Ltd. · Updated on 2026-08-17
988
Participants Needed
54
Research Sites
512 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Myval Transcatheter Heart Valve THV Series compared to Contemporary Valves, including the Sapien THV Series and Evolut THV Series, in patients with severe symptomatic native aortic valve stenosis. This multinational, prospective, randomized trial involves 768 participants and aims to assess whether the Myval device performs at least as well as the other commercially available valves in improving heart valve function.
Participants will be randomly assigned to receive either the Myval THV Series or one of the Contemporary Valves via a transfemoral approach. The Myval devices come in various sizes ranging from 20 mm to 29 mm, with additional registries for extra-large sizes. Separate study groups include a non-randomized nested registry for extra-large Myval devices and a lead-in set to ensure procedural adherence by investigators before enrolling subjects.
During the study, participants will undergo assessments including clinical evaluations and imaging to monitor valve function and safety over time. Outcomes measured include a combined safety and effectiveness endpoint at 30 days, as well as longer-term monitoring for mortality, stroke, kidney injury, valve performance, and quality of life up to 10 years. The study involves follow-ups at multiple timepoints to comprehensively evaluate the devices performance and patient health.
CONDITIONS
Brief Title
LANDMARK Trial: a Randomised Controlled Trial of Myval THV
Research Team
A
Ashok Thakkar, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patient or legal representative has provided written informed consent
Patient is eligible for transcatheter aortic valve implantation (TAVI) as assessed by local Heart Team
Patient is suitable for implantation with all three study valve devices
You will not qualify if you...
Patients unwilling to provide informed consent or whose legal heirs object to participation
Any condition that the investigator believes would make participation unsafe
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single procedure with follow-up
Participants receive implantation of either the Myval THV Series or a Contemporary Valve via transfemoral approach according to random assignment.
Initial implantation visit plus follow-up visits at multiple timepoints
Follow-up
Duration - Up to 10 years
Participants are monitored for safety, valve performance, and clinical outcomes over several years through scheduled visits and assessments.
Regular follow-up visits at pre-discharge, 30 days, 6 months, 1 year, and annually up to 10 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Prospective Study to Collect CT Imaging and Echocardiography Data for Predicting Outcomes After Transcatheter Aortic Valve Implantation
Evaluating Safety and Effectiveness of the Edwards SAPIEN X4 Balloon-Expandable Transcatheter Heart Valve for Treating Failing Aortic Bioprosthetic Valves
Study of Angiotensin Receptor Blockers to Slow Progression of Mild to Moderate Aortic Stenosis and Improve Heart Function
Heparin Reversal With Protamine Sulfate to Reduce Complications After Transcatheter Aortic Valve Replacement for Aortic Stenosis
Comparing Transcatheter and Surgical Aortic Valve Replacement in Patients Over 50 with Severe Aortic Valve Narrowing and Bicuspid Valve
Evaluating the EmStop Embolic Protection System Compared to the Sentinel Device During Self-Expanding Transcatheter Aortic Valve Replacement for Aortic Valve Stenosis
CardioHeartConnect Mobile Cardiac Rehabilitation Using Peloton Fitness Modules
Compared to Educational Materials for Patients Recovering from Transcatheter Aortic Valve Replacement
Clinical Outcomes and Valve Performance After Transcatheter Aortic Valve Replacement in Adults with Severe Aortic Valve Disease
Feasibility and Safety Study of the Point-Guard Embolic Protection Device During Transcatheter Aortic Valve Replacement TAVR
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Impact of Early Nonfatal Complications After Transcatheter Aortic Valve Implantation on 1-Year Mortality and Quality of Life: Insights From the LANDMARK Trial.
Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: The LANDMARK trial.
LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.
Andreas Baumbach, Niels van Royen, Ignacio J Amat-Santos...